SEOUL, Aug. 10 (Korea Bizwire) — SK Biopharmaceuticals Co., a biopharmaceutical affiliate of SK Group, said Thursday its net loss narrowed in the second quarter from a year earlier thanks to stellar overseas sales of its flagship epilepsy medication. Its net deficit for the April-June period reached 23.3 billion won (US$17.7 million) on a consolidated [...]
SEOUL, July 18 (Korea Bizwire) — SK Biopharmaceuticals Co., a pharmaceutical affiliate of South Korea’s SK Group, said Tuesday that its signature anti-epilepsy treatment, Xcopri, could generate US$1 billion in sales in the United States in 2029. Xcopri, or cenobamate, is a medication for partial-onset seizures in adults discovered by SK Biopharmaceuticals and its U.S. [...]
SEOUL, May 11 (Korea Bizwire) — SK Biopharmaceuticals Co., a biopharmaceutical affiliate of SK Group, said Thursday its first-quarter net loss narrowed from a year earlier thanks to robust sales of its flagship epilepsy medication. The company said in a regulatory filing its net loss for the January-March period reached 2.4 billion won (US$1.8 million) [...]
SEOUL, July 18 (Korea Bizwire) — SK Biopharmaceuticals Co. Ltd., a unit of South Korean conglomerate SK Group, is likely to be added to the list of 200 major stocks listed on the main bourse in September, as its market capitalization has run high for a certain period after its market debut, industry sources said [...]
SEOUL, July 2 (Korea Bizwire) — SK Biopharmaceuticals Co. Ltd., the largest initial public offering (IPO) of the year so far, made a strong market debut Thursday, finishing at more than two times the IPO price. The unit of South Korean conglomerate SK Group closed at 127,000 won (US$105), rising by a daily permissible limit [...]
SEOUL, July 1 (Korea Bizwire) — SK Biopharamaceuticals Co. Ltd., a unit of South Korean conglomerate SK Group, will make a debut on the local bourse this week, probably emerging as the top pick by investors for its growth potential amid the coronavirus pandemic. The initial public offering (IPO) price of SK Biopharmaceutical was set at [...]
SEOUL, May 20 (Korea Bizwire) — South Korean drug firm SK Biopharmaceuticals Co. has filed a formal application for its share listing scheduled for May, industry sources said Wednesday. The biopharmaceutical unit of South Korean conglomerate SK Group on Tuesday submitted a so-called registration statement to the country’s financial authorities in the runup to the [...]
SEOUL, Nov. 22 (Korea Bizwire) — SK Biopharmaceuticals Co., a biopharmaceutical affiliate of South Korea’s SK Group, said Friday its anti-epileptic drug has won approval from the U.S. Food and Drug Administration (FDA). SK Biopharmaceuticals said the FDA granted approval of XCOPRI, or cenobamate tablets, for the treatment of partial-onset seizures in adults. This is [...]
SEOUL, Aug. 22 (Korea Bizwire) — South Korean conglomerate SK Group is seeking to list its pharmaceutical unit on the country’s stock market by the end of this year, industry sources said Thursday. SK Holdings Co., the conglomerate’s holding firm, held a board meeting last month to pass a plan for SK Biopharmaceuticals Co.’s initial [...]
SEOUL, Mar. 21 (Korea Bizwire) — A biopharmaceutical affiliate of South Korea’s SK Group said Thursday that it has won sales approval from the U.S. Food and Drug Administration (FDA) for its sleep disorder drug. The product, named Solriamfetol, is the country’s first indigenous drug for the central nervous system to receive the greenlight from [...]